Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vyxeos and Clofarabine in Pediatric Relapsed/Refractory AML
NCT07156435Phase 1Recruiting
- Sponsor
- Princess Máxima Center for Pediatric Oncology
- Start
- Nov 2020
- Primary completion
- Dec 2026
- Countries
- 6
01
Overview
Phase 1, open-label trial of cytarabine in acute myeloid leukemia (AML), sponsored by Princess Máxima Center for Pediatric Oncology. Started Nov 2020; status: recruiting.
02
Drugs
cytarabine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT07156435.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07156435.